Latest Zyprexa Stories
INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Nine percent revenue growth driven by higher volume continues strong trend for the year. 21 percent of Q2 revenue invested in R&D to advance pipeline of nearly 70 potential new medicines in clinical development. Ongoing cost-containment efforts support double-digit growth in operating income. Q2 earnings per share grow to $1.22 (reported), or $1.24 (non-GAAP). 2010 earnings per share guidance range raised to $4.44 to $4.59 (reported),...
- Exultant; jubilant; triumphant; on the high horse.
- Tipsy; slightly intoxicated.